Last reviewed 2026-05-14 · How we verify

E coli H10407 and buffer

Johns Hopkins Bloomberg School of Public Health · Phase 1 active Biologic

E coli H10407 and buffer is a Biologic drug developed by Johns Hopkins Bloomberg School of Public Health. It is currently in Phase 1 development.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	E coli H10407 and buffer
Sponsor	Johns Hopkins Bloomberg School of Public Health
Modality	Biologic
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

E coli H10407 and buffer CI brief — competitive landscape report
E coli H10407 and buffer updates RSS · CI watch RSS
Johns Hopkins Bloomberg School of Public Health portfolio CI

Frequently asked questions about E coli H10407 and buffer

What is E coli H10407 and buffer?

E coli H10407 and buffer is a Biologic drug developed by Johns Hopkins Bloomberg School of Public Health.

Who makes E coli H10407 and buffer?

E coli H10407 and buffer is developed by Johns Hopkins Bloomberg School of Public Health (see full Johns Hopkins Bloomberg School of Public Health pipeline at /company/johns-hopkins-bloomberg-school-of-public-health).

What development phase is E coli H10407 and buffer in?

E coli H10407 and buffer is in Phase 1.

Manufacturer: Johns Hopkins Bloomberg School of Public Health — full pipeline

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing